The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000775314p
Ethics application status
Help: Ethics application status
Not yet submitted
Date submitted
Help: Date submitted
19/05/2026
Date registered
Help: Date registered
29/06/2026
Date last updated
Help: Date last updated
29/06/2026
Date data sharing statement initially provided
Help: Data sharing statement date
29/06/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
A pilot randomized clinical trial to assess whether magnetic acupuncture reduces pain prior to painful procedures (heel prick) in neonates by comparing changes in cortisol levels and pain scores.
Scientific title
A pilot randomized clinical trial to assess whether magnetic acupuncture reduces pain prior to painful procedures (heel prick) in neonates by comparing changes in cortisol levels and pain scores.
Additional trial identifiers [1] 317325 0
Nil
Universal Trial Number (UTN)
Trial acronym
SERENUM trial (StrEss REduction in Neonates Using Magnetic acupuncture)
Related trial records

Health condition
Health condition(s) studied:
pain 341975 0
preterm 342375 0
Condition category
Condition code
Anaesthesiology 338055 338055 0 0
Pain management
Reproductive Health and Childbirth 338056 338056 0 0
Complications of newborn

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
The magnetic acupuncture (MA) stickers (Sakamura, Helio Acupuncture, Japan) will be applied bilaterally in both ears to the five auricular acupuncture points as per the Battlefield Acupuncture (BFA) at least 30 minutes prior to a heel prick by the unblinded investigator.
The BFA protocol has been used in both adults and children for management of acute pain conditions. All unblinded investigators administering the intervention will complete a one-hour BFA workshop delivered by experienced BFA practitioner, All infants will receive standard care including sucrose prior to heel prick per local NICU guidelines; additional analgesic measures remain at clinical discretion.

Stickers will remain in place for a maximum of three days or just prior to discharge from the neonatal unit, when they will be removed. Each infant will be followed up for the duration of the MA or placebo intervention, and stickers will be checked every eight hours by bedside nurses.

The magnets have a strength of 100G and measure 1.7 mm in diameter on a circular sticker of surgical tape with diameter 10 mm. These magnets have already been used for pain management in the neonatal population with no side effects reported.
Intervention code [1] 334113 0
Treatment: Other
Intervention code [2] 334428 0
Prevention
Intervention code [3] 334554 0
Treatment: Devices
Description of the comparator or control
Placebos will be constructed by removing the magnet ball from pre-commercially available MA stickers (Sakamura, Helio Acupuncture, Japan). The magnet site on placebo and magnetic stickers will be concealed prior to sticker placement with a thick application of white, opaque correction fluid. Hence, no magnet will be applied to the placebo group.
The placebo stickers (Sakamura, Helio Acupuncture, Japan) will be applied bilaterally to the five auricular acupuncture points as per the Battlefield Acupuncture (BFA) at least 30 minutes prior to a heel prick by the unblinded investigator.
The BFA protocol has been used in both adults and children for the effective management of acute pain conditions. All unblinded investigators administering the intervention will complete a one-hour BFA workshop delivered by experienced BFA practitioner, The training duration has previously been shown to be sufficient for non-acupuncturist healthcare workers. All infants will receive standard care including sucrose prior to heel prick per local NICU guidelines; additional analgesic measures remain at clinical discretion.

Stickers will remain in place for a maximum of three days or just prior to discharge from the neonatal unit, when they will be removed. Each infant will be followed up for the duration of the MA or placebo intervention, and stickers will be checked every eight hours by bedside nurses.
Control group
Placebo

Outcomes
Primary outcome [1] 345465 0
Stress
Timepoint [1] 345465 0
baseline (30 min before MA sticker placement) and 30 min after MA sticker placement.
Primary outcome [2] 345466 0
Pain
Timepoint [2] 345466 0
15 minutes before, during, and 15 minutes after heel prick
Secondary outcome [1] 461771 0
pain / stress (this will be assessed as a composite outcome)
Timepoint [1] 461771 0
continuous monitoring during heel prick
Secondary outcome [2] 461773 0
Adverse events
Timepoint [2] 461773 0
For the duration of the magnetic acupuncture stickers intervention (stickers will remain in place for a maximum of three days or just prior to discharge from the neonatal unit, when they will be removed)
Secondary outcome [3] 461774 0
Parent / guardian satisfaction
Timepoint [3] 461774 0
Post intervention (at least 30 min post MA)

Eligibility
Key inclusion criteria
• Neonates born at greater than or equal to 29 weeks gestational age and/or greater than or equal to 1,000 grams;
• Admitted to the Special Care Baby Unit (SCBU) or Neonatal Intensive Care Unit (NICU) at SCUH;
• Clinically indicated heel prick required during admission;
• Written informed parental/guardian consent obtained prior to enrolment.
Minimum age
No limit
Maximum age
1 Months
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
• Currently requiring invasive respiratory support, sedation or humidification;
• Major congenital abnormality interfering with pain perception;
• Neurological conditions impairing pain perception;
• Opioid or sedative treatment within 24 hours prior to the scheduled heel prick.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Following parental consent, infants will be randomised to receive either MA or placebo stickers. Allocation will be concealed using REDCap randomisation, with group assignment revealed only after participant enrolment.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Redcap will be used for randomization with variable block sizes of 4 and 6. The randomization sequence will be computed-generated in block sizes of four, stratified for gestational age (preterm less than 37 weeks’ gestation or term greater than or equal to 37 weeks’ gestation). If gestation is unknown at birth, babies will be stratified based on the gestational age using the New Ballard Score.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s

The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Other design features
Phase
Not Applicable
Type of endpoint/s
Safety/efficacy
Statistical methods / analysis
Neonatal salivary cortisol rises with stress but also with natural circadian rhythm patterns, leading to substantial variations between individuals and times of day. That is why, for cortisol measurements, it will be the difference between pre- and post-procedure that will be used (change value). Published neonatal salivary cortisol data show that infants in early inpatient settings exhibit mean salivary cortisol concentrations of approximately 4.3 ng/dL (SD ˜ 2.65 ng/dL) on day 2 of life, consistent with a stress response compared with infants at home (~1.0 ng/dL). As acupuncture is unlikely to abolish the full stress response, this study is powered to detect a more conservative between-group difference in change in salivary cortisol of 1.6 ng/dL, corresponding to a standardized effect size (Cohen’s d) of approximately 0.6 (medium effect size). Assuming a two-group repeated-measures design (pre- and post-procedure), a correlation of 0.5 between repeated measures, a two-sided alpha of 0.05, and 80% power to detect a Group × Time interaction, a total of 48 infants (24 per group) is required. To account for an anticipated 10% attrition rate due to potential loss to follow-up or unusable saliva samples, our recruitment target is 54 infants (27 per group).
Results will be analysed on an intention-to-treat basis. Demographic characteristics will be compared between the groups using chi-square and Fisher Exact tests, or student's t-tests and Mann–Whitney U tests as appropriate. Differences between the treatment arms for our primary outcome cortisol levels, pain scales (PAT) and secondary outcomes of HR and SpO2 will be analysed using mixed ANOVA to account for between and within subject factors. We will use two-sided alpha 0.05 and correct for multiple testing with p values <0.05 considered significant and Confidence Interval of 95%. All statistical analyses will be carried out in SPSS (version 23.0; IBM; Chicago, IL, USA). Descriptive analysis will be used to describe further results from parents’ perceptions and feedback questionnaire. The results will only be reported and published in aggregate, with care to ensure that there are no individual identifiers.

Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 29532 0
Sunshine Coast University Hospital - Birtinya
Recruitment postcode(s) [1] 45851 0
4575 - Birtinya

Funding & Sponsors
Funding source category [1] 321892 0
Charities/Societies/Foundations
Name [1] 321892 0
Wishlist / SERTF - Sunshine Coast University Hospital
Country [1] 321892 0
Australia
Primary sponsor type
Hospital
Name
Sunshine Coast University hospital
Address
Country
Australia
Secondary sponsor category [1] 324755 0
None
Name [1] 324755 0
Address [1] 324755 0
Country [1] 324755 0

Ethics approval
Ethics application status
Not yet submitted
Ethics committee name [1] 320432 0
Mater Misericordiae Ltd Human Research Ethics Committee
Ethics committee address [1] 320432 0
Ethics committee country [1] 320432 0
Australia
Date submitted for ethics approval [1] 320432 0
30/06/2026
Approval date [1] 320432 0
Ethics approval number [1] 320432 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 150462 0
Dr Poliana De Barros Medeiros
Address 150462 0
Sunshine Coast University Hospital, 6 Doherty Street, Birtinya, Queensland 4575
Country 150462 0
Australia
Phone 150462 0
+61 452155812
Fax 150462 0
Email 150462 0
Contact person for public queries
Name 150463 0
Poliana De Barros Medeiros
Address 150463 0
Sunshine Coast University Hospital, 6 Doherty Street, Birtinya, Queensland 4575
Country 150463 0
Australia
Phone 150463 0
+61 452155812
Fax 150463 0
Email 150463 0
Contact person for scientific queries
Name 150464 0
Poliana De Barros Medeiros
Address 150464 0
Sunshine Coast University Hospital, 6 Doherty Street, Birtinya, Queensland 4575
Country 150464 0
Australia
Phone 150464 0
+61 452155812
Fax 150464 0
Email 150464 0

Data sharing statement
Will the study consider sharing individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.